Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4424-4431

  Han, K ^a,h   Capitano, B ^a,b   Bies, R ^a,c,d   Potoski, B A ^a   Husain, S ^a,e   Gilbert, S ^a   Paterson, D L ^a,f   McCurry, K ^a,g   Venkataramanan, R ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Pfizer Global Pharmaceuticals   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g LERNER RESEARCH INSTITUTE   (United States)

^h GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; COMPARTMENT MODEL; CYSTIC FIBROSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG INFUSION; FEMALE; GRAFT RECIPIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERBARISM; KINETICS; LUNG TRANSPLANTATION; MALE; MONTE CARLO METHOD; MYCOSIS; POPULATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; VITAL CAPACITY;

ADULT; AGED; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PYRIMIDINES; TRIAZOLES; YOUNG ADULT;

EID: 77957358110     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00504-10     Document Type: Article

References (33)

1. Andes, D., K. Marchillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169.
2. Berge, M., R. Guillemain, V. Boussaud, M. H. Pham, P. Chevalier, A. Batisse, C. Amrein, E. Dannaoui, M. A. Loriot, A. Lillo-Le Louet, and E. M. Billaud. 2009. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl. Infect. Dis. 11:211-219.
3. Bowers, L. D., and D. M. Canafax. 1984. Cyclosporine: experience with therapeutic monitoring. Ther. Drug Monit. 6:142-147.
4. Boyd, A. E., S. Modi, S. J. Howard, C. B. Moore, B. G. Keevil, and D. W. Denning. 2004. Adverse reactions to voriconazole. Clin. Infect. Dis. 39:1241-1244.
5. Christenson, J. T., M. Schmuziger, J. Maurice, F. Simonet, and V. Velebit. 1994. Postoperative visceral hypotension the common cause for gastrointestinal complications after cardiac surgery. Thorac. Cardiovasc. Surg. 42:152-157.
6. Cox, K. L., J. N. Isenberg, and M. E. Ament. 1982. Gastric acid hypersecretion in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 1:559-565.
7. Denning, D. W., P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.
8. Eggermont, E., and K. De Boeck. 1991. Small-intestinal abnormalities in cystic fibrosis patients. Eur. J. Pediatr. 150:824-828.
9. Ferguson, J. H., and A. B. Chang. 2009. Vitamin D supplementation for cystic fibrosis. Cochrane Database Syst. Rev. 2009(4):CD007298.
10. Fondacaro, J. D., J. E. Heubi, and F. W. Kellogg. 1982. Intestinal bile acid malabsorption in cystic fibrosis: a primary mucosal cell defect. Pediatr. Res. 16:494-498.
11. Freifeld, A., S. Arnold, W. Ooi, F. Chen, T. Meyer, L. J. Wheat, M. Smedema, A. Lemonte, and P. Connolly. 2007. Relationship of blood level and susceptibility in voriconazole treatment of histoplasmosis. Antimicrob. Agents Chemother. 51:2656-2657.
12. Han, E. E., P. M. Beringer, S. G. Louie, M. A. Gill, and B. J. Shapiro. 2004. Pharmacokinetics of Ibuprofen in children with cystic fibrosis. Clin. Pharmacokinet. 43:145-156.
13. Han, K., R. Bies, H. Johnson, B. Capitano, D. Blisard, S. Husain, P. K. Linden, A. Marcos, E. J. Kwak, B. Potoski, D. L. Paterson, and R. Venkataramanan. 2009. Population pharmacokinetic analysis of voriconazole in liver transplant patients. Abstracts of the ASCPT Annual Meeting. ASCPT, Washington, DC.
14. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
15. Johnson, H. J., K. Han, B. Capitano, D. Blisard, S. Husain, P. K. Linden, A. Marcos, E. J. Kwak, B. Potoski, D. L. Paterson, M. Romkes, and R. Venkataramanan. 2010. Voriconazole pharmacokinetics in liver transplant recipients. Antimicrob. Agents Chemother. 54:852-859.
16. Kalivianakis, M., and H. J. Verkade. 1999. The mechanisms of fat malabsorption in cystic fibrosis patients. Nutrition 15:167-169.
17. Karlsson, M. O., I. Lutsar, and P. A. Milligan. 2009. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 53:935-944.
18. Kennedy, J. M., and A. M. Riji. 1998. Effects of surgery on the pharmacokinetic parameters of drugs. Clin. Pharmacokinet. 35:293-312.
19. Lin, S. J., J. Schranz, and S. M. Teutsch. 2001. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32:358-366.
20. Neely, M., T. Rushing, A. Kovacs, R. Jelliffe, and J. Hoffman. 2010. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50:27-36.
21. Nomura, K., Y. Fujimoto, Y. Kanbayashi, K. Ikawa, and M. Taniwaki. 2008. Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies. Eur. J. Clin. Microbiol. Infect. Dis. 27:1141-1143.
22. Panackal, A. A., A. Dahlman, K. T. Keil, C. L. Peterson, L. Mascola, S. Mirza, M. Phelan, B. A. Lasker, M. E. Brandt, J. Carpenter, M. Bell, D. W. Warnock, R. A. Hajjeh, and J. Morgan. 2003. Outbreak of invasive aspergillosis among renal transplant recipients. Transplantation 75:1050-1053. (Pubitemid 36438538)
23. Pascual, A., T. Calandra, S. Bolay, T. Buclin, J. Bille, and O. Marchetti. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211.
24. Pfizer. VFEND® IV (voriconazole) for injection, VFEND® tablets, VFEND® for oral suspension.
25. Potoski, B. A., and J. Brown. 2002. The safety of voriconazole. Clin. Infect. Dis. 35:1273-1275.
26. Scott, L. J., and D. Simpson. 2007. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67:269-298. (Pubitemid 46259330)
27. Smith, J., N. Safdar, V. Knasinski, W. Simmons, S. M. Bhavnani, P. G. Ambrose, and D. Andes. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
28. Tan, K., N. Brayshaw, K. Tomaszewski, P. Troke, and N. Wood. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46:235-243.
29. Theuretzbacher, U., F. Ihle, and H. Derendorf. 2006. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45:649-663.
30. Tsang, V. T., A. Johnston, F. Heritier, N. Leaver, M. E. Hodson, and M. Yacoub. 1994. Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. Eur. J. Clin. Pharmacol. 46:261-265.
31. Walsh, T. J., E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis, K. A. Marr, V. A. Morrison, B. H. Segal, W. J. Steinbach, D. A. Stevens, J. A. van Burik, J. R. Wingard, and T. F. Patterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
32. Walsh, T. J., M. O. Karlsson, T. Driscoll, A. G. Arguedas, P. Adamson, X. Saez-Llorens, A. J. Vora, A. C. Arrieta, J. Blumer, I. Lutsar, P. Milligan, and N. Wood. 2004. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48:2166-2172.
33. Zheyu, C., and Y. Lunan. 2006. Early changes of small intestine function in rats after liver transplantation. Transplant Proc. 38:1564-1568. (Pubitemid 43912786)